Acute Heart Failure - COngestion Discharge Evaluation

Acute heart failure (AHF) is a major public health problem, associated with a 40% risk of death or re-hospitalisation at 3 months. This risk is significantly increased by insufficient decongestion at the end of hospitalisation for AHF assessed by a standardised clinical score, a natriuretic peptide dosage or by cardiac and pulmonary ultrasound . Adapting treatment according to lung congestion assessed by implantable devices (not reimbursed in France) improves the prognosis. However, due to the lack of a standardised congestion assessment, therapeutic adaptation in acute heart failure is currently empirical. The best multimodality approach to congestion evaluation is uncertain.

NCT Number	NCT04332692
Lead Sponsor	Central Hospital, Nancy, France
Conditions	Acute Heart Failure
Enrollment	110 participants
Start Date	2020-07-15
Primary Completion	2026-08-20 (estimated)
Study Completion	2028-05-20 (estimated)
Updated on ClinicalTrials.gov	2023-06-05